clinical trial · NCT01601808
Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma
University of Liverpool·phase2·completed·n = 142
Pancreatic CancerPlaceboCaprelsa (vandetanib)
brief summary
ViP is a double blinded clinical trial which will compare gemcitabine and vandetanib chemotherapy with gemcitabine alone in patients with locally advanced or metastatic pancreatic carcinoma.
started
Oct 10, 2011
primary completion
Sep 5, 2018
completion
Sep 5, 2018
last updated
Mar 13, 2025
official title
A Prospective, Phase II, Double Blinded, Multicentre, Randomised Clinical Trial Comparing Combination Gemcitabine and Vandetanib Therapy With Gemcitabine Therapy Alone in Locally Advanced or Metastatic Pancreatic Carcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol